CBSET announced that its scientists have published data and analyses that provide critical insights into the interplay between target anatomy and device attributes in determining balloon- and stent-based paclitaxel retention in healthy and diseased arteries. According to CBSET, these findings may transform the understanding of the safety and efficacy of paclitaxel-coated devices used in the […]
Category Archives: News
Press Release: Computational model of coating and tissue morphology determinants of balloon based drug retention and tissue dosing suggest a new paradigm for accelerated treatment optimization: CBSET data published in Journal of Controlled Release
“This mechanistic model empowers and reassures clinicians about the amount of active paclitaxel that our patients are exposed to, while offering insights and a framework for accelerating the preclinical development of new technologies such as those including sirolimus,” said Sahil A. Parikh, M.D., co-author and Director of Endovascular Services at the Columbia University College of […]
Endovascular Today: Computational Model Suggests a New Paradigm for Accelerated Treatment Optimization With Paclitaxel Devices
August 28, 2019—CBSET announced that its scientists have published data and analyses that provide critical insights into the interplay between target anatomy and device attributes in determining balloon- and stent-based paclitaxel retention in healthy and diseased arteries. According to CBSET, these findings may transform the understanding of the safety and efficacy of paclitaxel-coated devices used […]
Press Release: The procedural and anatomical determinants of second-generation renal denervation therapy are explained by local tissue anatomy, suggesting a new paradigm for treatment optimization: CBSET data published in Hypertension
“The combination of quantitative preclinical experiments and computational models have expanded our understanding of the mechanisms that facilitate circumferential nerve ablation and clinical efficacy. These data help complete the puzzle for device innovators, and aid in the advancement of specific approaches to treat diseases involving sympathetic denervation and modulation,” said Peter M. Markham, President and […]
CRT19 Best Innovation Competition: Enhanced Plaque Modification of Cadaveric Human Calcified Peripheral Arteries Treated with a Vessel Preparation System
Watch: Interview of CBSET’s Director of Research and Innovation, Rami Tzafriri, PhD, by Michael Mooney, MD, of Minneapolis Heart Institute, Abbott Northwestern hospital, at CRT19. Dr. Tzafriri discusses CBSET’s human cadaver model assessment of a vessel preparation system and the attributes of this particular technology that suggest it might be conducive to enhancing drug absorption.
Not a Single Drug Is Approved to Treat Hearing Loss, but Now There Is Hope
CBSET / CILcare Partnership Supports “World Hearing Day 2019,” Sponsored by the World Health Organization (WHO) on March 3rd, to Make Hearing a Priority 1. Hearing loss is at epidemic prevalence. According to the National Institutes of Health (NIH), about three out of every 1,000 children in the United States are born with a detectable level […]
Press Release: CBSET partner CILcare leads Phase 2 of $2.1 million total DETECT project to develop a preclinical model for tinnitus drug therapy development
LEXINGTON, Mass., and MONTPELLIER, France, Nov. 12, 2018 — CBSET partner CILcare, a world-leading CRO (clinical research organization) specialized in the research and development of drugs and medical devices in the field of hearing, has initiated the second phase of its ongoing tinnitus research project, DETECT, a public/private project being conducted in collaboration with the […]
Press Release: Preclinical safety studies demonstrate that drug presence can accentuate pathological responses at stent fracture sites
“These findings could potentially have a seminal effect on development of innovative DES coating designs to treat coronary artery disease,” said Rami Tzafriri, Ph.D., Director of Research and Innovation, CBSET. “Animal models of real-world scenarios such as stent fracture offer an exciting opportunity to differentiate the relative effectiveness of novel drug eluting stent designs that […]
Press Release: Study Validates New Approach for Optimizing Endovascular Drug Delivery Using Stents with a Deployable Coating That Enhances Sirolimus Distribution Compared to Traditional DES
“Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings” published online in Journal of Controlled Release “This preclinical demonstration of the enhanced and more uniform drug and biomarker distribution by stents with deployable coatings could lead to more rapid and improved healing after stent implantation,” said David Kandzari, M.D., Director […]
Press Release: Preclinical safety studies must include equally balanced male/female animal models to shed light on sex-dependent vascular responses in humans
“Sex Differences in the Outcomes of Stent Implantation in Mini-Swine Model” published in PLOS ONE “Retrospective analyses of pooled animal data can provide important insights into sex-dependent anatomic and pathophysiologic differences,” said Rami Tzafriri, PhD, Director of Research and Innovation, CBSET. LEXINGTON, Mass., Feb. 12, 2018 – CBSET, a non-for-profit preclinical research institute dedicated to […]